Washington is currently home to 1729 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485
Recruiting
FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
12/21/2023
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Low-grade Glioma, Advanced Solid Tumor
Register for Updates
Pre-operative Education Modalities to Decrease Opioid Use
NCT04933084
Recruiting
This is a triple-armed, randomized, controlled, non-blinded trial to study the effect of preoperative patient education in conjunction with a limited opioid peri-operative analgesia program on post-operative opioid use following radical prostatectomy. Patients will be randomized into three education arms: usual care (variable provider-dependent education), text handout, or text handout and pre-recorded video. The impact of patient education on outcomes of in-hospital, post-discharge, and persist... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Virginia Mason Medical Center, Seattle, Washington
Conditions: Prostatectomy, Opioid-Related Disorders
Register for Updates
A Dyadic Approach to Perinatal Depression in Primary Care: Maternal Infant and Dyadic Care
NCT04998721
Recruiting
The purpose of this study is to assess the effectiveness of a parenting intervention+usual care compared to usual care on postpartum depression and other mental health and parenting outcomes, as well as the feasibility and acceptability of the parenting intervention.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2023
Locations: Amritha Bhat, Seattle, Washington
Conditions: Depression, Postpartum, Efficacy, Self, Anxiety
Register for Updates
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
NCT06164717
Recruiting
This study meets the NIH definition of a clinical trial, but is not a treatment study. Instead, the goal of this study is to investigate how hearing ourselves speak affects the planning and execution of speech movements. The study investigates this topic in both typical speakers and in patients with Deep Brain Stimulation (DBS) implants. The main questions it aims to answer are: * Does the way we hear our own speech while talking affect future speech movements? * Can the speech of DBS patients... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
12/01/2023
Locations: University of Washington, Seattle, Washington
Conditions: Speech
Register for Updates
PRISM Race and Communication Pilot RCT
NCT04915079
Recruiting
This is a pilot randomized trial of 60 patients to test feasibility, acceptability and efficacy of PRISM to improve resilience and facilitate improved patient-clinician communication in racially minorities patients with serious illness.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: University of Washington - Harborview Medical Center, Seattle, Washington
Conditions: Discrimination, Racial, Communication, Chronic Illness, Bias, Racial
Register for Updates
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022
Recruiting
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) or in subjects with Ph+ B-cell precursor (BCP) ALL or lymphoid blast phase CML (CML LBP), who have experienced resistance or intolera... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
Register for Updates
Pediatric Vasculitis Initiative
NCT02006134
Recruiting
Childhood chronic vasculitis describes a group of rare life-threatening diseases that have in common inflammation of blood vessels in vital organs such as kidneys, lungs and brain. Most knowledge about them comes from adult patients. Severe disease requires aggressive life-saving treatments with steroids and some cancer drugs which can themselves cause damage, and increase risks of cancer and severe infections. Conversely, milder disease can be treated with less toxic drugs. Different classifica... Read More
Gender:
ALL
Ages:
20 years and below
Trial Updated:
11/27/2023
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Wegeners Granulomatosis (Granulomatosis With Polyangiitis), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Primary CNS Vasculitis, Unclassified Vasculitis, Eosinophilic Granulomatosis With Polyangiitis
Register for Updates
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
NCT04839991
Recruiting
FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to determine MTD and preliminary RP2D.In addition this study will assess the safety and efficacy of CB307 when given in combination with pembrolizumab (KEYTRUDA®) in patients with metastatic PSMA+ castration-resistant cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: University of Washington, Seattle, Washington
Conditions: Advanced and/or Metastatic Solid Tumours
Register for Updates
Evaluating Impact of Systane iLux on Dryness Symptoms and Wearing Time in Contact Lens Users
NCT05306561
Recruiting
To evaluate dry eye symptoms and contact lens wearing times after a single iLux treatment by evaluating change from baseline in OSDI scores, subjective CLDEQ8 and CL wearing time questionnaires, and meibomian gland secretion scores.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Periman Eye Institute, Seattle, Washington
Conditions: Meibomian Gland Dysfunction, Dry Eye
Register for Updates
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03110822
Recruiting
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Northwest Medical Specialists, PPLC, Tacoma, Washington
Conditions: Multiple Myeloma
Register for Updates
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
NCT04964518
Recruiting
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose expansion phase (Part II)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/23/2023
Locations: Swedish Medical Center, Seattle, Washington
Conditions: AML, Adult
Register for Updates
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
NCT04858776
Recruiting
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and imp... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
10/17/2023
Locations: Lake Washington Vascular, Bellevue, Washington
Conditions: Iliofemoral; Thrombosis
Register for Updates